Hormonal
Higher early adult BMI (ages 18-30) is inversely associated with breast cancer risk in both pre- and postmenopausal women, suggesting a protective effect of higher adiposity during young adulthood.
Maintain a healthy weight during young adulthood (18-30), as higher early adult BMI may offer some protection against breast cancer later in life. However, avoid adult weight gain, which increases risk.
Greater early adult BMI (ages 18–30 years) was significantly inversely associated with premenopausal breast cancer... Inverse association of similar magnitude was observed for postmenopausal breast cancer
Why this rating
Meta-analysis of 13 studies for premenopausal and 18 for postmenopausal women showing significant inverse associations.
Source
World Cancer Research Fund International: Continuous Update Project—systematic literature review and meta-analysis of observational cohort studies on physical activity, sedentary behavior, adiposity, and weight change and breast cancer risk
Doris S.M. Chan et al. · Cancer Causes & Control · 2019
DOI 10.1007/s10552-019-01223-w
More from this paper
- Higher levels of physical activity, particularly vigorous intensity, are inversely associated with the risk of developing breast cancer in both premenopausal and postmenopausal women.Good
- Increased body adiposity, specifically higher BMI and adult weight gain, significantly increases the risk of breast cancer in postmenopausal women, particularly for hormone receptor-positive (HR+) tumors.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →